UK Markets closed

Atossa Therapeutics, Inc. (ATOS)

NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
1.4600+0.0500 (+3.55%)
At close: 04:00PM EST
1.5000 +0.04 (+2.74%)
After hours: 07:35PM EST

Atossa Therapeutics, Inc.

107 Spring Street
Seattle, WA 98104
United States
206 325 6068

Full-time employees6

Key executives

NameTitlePayExercisedYear born
Dr. Steven C. QuayChairman, CEO & Pres944.57kN/A1951
Mr. Kyle Guse CPA, Esq., CPACFO, Gen. Counsel & Sec.624.13kN/A1964
Ms. Heather ReesVP of Fin. & AccountingN/AN/AN/A
Ms. Delly Behen P.H.R.VP of Admin. & HRN/AN/AN/A
Ms. Janet Rose Rea MSPH, RACSr. VP of Regulatory, Quality & Clinical AffairsN/AN/AN/A
Amounts are as of 31 December 2020, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Atossa Therapeutics, Inc., a clinical-stage biopharmaceutical company, discovers and develops medicines in the areas of oncology and infectious diseases. The company's lead program is Endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer. It is also developing AT-301, a proprietary drug candidate for nasal administration in patients diagnosed with COVID-19; AT-H201, a drug candidate to improve lung function in COVID-19 patients; and immunotherapy/chimeric antigen receptor therapy programs for the treatment of breast cancer. Atossa Therapeutics, Inc. has a research agreement with Dana-Farber Cancer Institute, Inc. to support research of cytokine-coated nanoparticles for the potential treatment of breast cancer. The company was formerly known as Atossa Genetics Inc. and changed its name to Atossa Therapeutics, Inc. in January 2020. Atossa Therapeutics, Inc. was founded in 2008 and is headquartered in Seattle, Washington.

Corporate governance

Atossa Therapeutics, Inc.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.